Tolerance induction by intrathymic injection of allopeptides.

通过胸腺内注射同种肽诱导耐受。

基本信息

  • 批准号:
    07807109
  • 负责人:
  • 金额:
    $ 1.54万
  • 依托单位:
  • 依托单位国家:
    日本
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
  • 财政年份:
    1995
  • 资助国家:
    日本
  • 起止时间:
    1995 至 1996
  • 项目状态:
    已结题

项目摘要

PURPOSE : One of possible methods to achieve donor specific tolerance is intrathymic injection of donor antigen, but no report was available about intrathymic injection of peptides of donor MHC class I molecules. In order to analyze the role of HLA class I molecules on graft rejection, two different HLA class I transgenic mice were selected and transplantation was performed. In addition, peptides from one of the HLA class I were injected intrathymically to the other HLA class I transgenic mouse to study the possibility of specific tolerance induction.METHODS : A skin graft from an HLA-B35 transgenic mouse (HLA-B35TGM), in which the HLA-B35^*01 gene is transfected to C3H/He, was transplanted to HLA-B51 transgenic mice (HLA-B51TGM), in which the HLA-B51^*01 gene is transfected to C3H/He. Seven kinds of 23 to 25 mer synthetic peptides, representing full sequences of the polymorphic lesion of HLA-B35, were injected to the thymus of HLA-B51TGM.Two days after intrathymic injection, HLA-B35TG … More M heart was transplanted. Rejection of the heart graft was judged by palpation and histopathological findings. Standard CML assay was performed between the transgenic mice to study the specific cellular cytotoxity.RESULTS : Skin grafts from HLA-B35TGM transplanted to HLA-B51TGM were rejected 12.6 (]SY.+-。[) 4.2 days (mean (]SY.+-。[) SD) after transplantation. Specific cytotoxity was detected by CML assay and this effect was significant when responder cells were primed by skin grafting. Heart grafts from HLA-B35 TGM transplanted into HLA-B51TGM was rejected on 22.8 (]SY.+-。[) 4.2 days after transplantation, whereas mean heart graft survival was more than 60 days when some HLA-B35 peptides were injected intrathymically to HLA-B51TGM prior to heart transplantation.CONCLUSIONS : 1. HLA-B51TGM reject HLA-B35TGM skin and heart graft mainly by cellular mechanism, and these mice are useful to study the role of HLA class I molecules on graft rejection. 2. Intrathymic injection of peptides derivedfrom donor HLA class I molecules has a great chance to induce donor specific tolerance. Less
目得:胸腺内注射供者抗原是获得供者特异性免疫耐受的可能方法之一,但胸腺内注射供者MHC I类分子多肽的研究未见报道。为了分析HLA I类分子在移植排斥反应中的作用,选择了两种不同的HLA I类转基因小鼠并进行移植。另外,将来自其中一种HLA I类的肽注射到另一种HLA I类转基因小鼠的胸腺内,以研究特异性耐受诱导的可能性。HLA-B35转基因小鼠的皮肤移植将其中HLA-B35^*01基因转染至C3 H/He的HLA-B35 TGM移植至HLA-B51转基因小鼠(HLA-B51 TGM),其中HLA-B51^*01基因被转染至C3 H/He。将代表HLA-B_(35)多态性损伤区全序列的7种23 ~ 25聚体合成肽注射到HLA-B_(51)TGM胸腺内,注射后2天,HLA-B_(35)TG ...更多信息 我的心脏被移植了。通过触诊和组织病理学检查判断心脏移植物的排斥反应。结果:HLA-B51 TGM与HLA-B35 TGM的皮肤移植物排斥反应为12.6(± SD)。[)4.2天(平均()SY. ±.(SD)。CML检测特异性细胞毒性,当反应细胞通过皮肤移植致敏时,这种效应是显著的。HLA-B_(35)TGM移植于HLA-B_(51)TGM的心脏移植物在22.8(±)SY时发生排斥反应。移植后平均存活时间为4.2天,而在心脏移植前胸腺内注射HLA-B51 TGM的HLA-B35肽段,移植心脏平均存活时间超过60天。HLA-B51 TGM主要通过细胞机制对HLA-B35 TGM皮肤和心脏移植物产生排斥反应,为进一步研究HLA-B35 TGM Ⅰ类分子在移植排斥反应中的作用提供了实验动物模型。2.胸腺内注射供者HLA-I类分子衍生肽有很大机会诱导供者特异性免疫耐受。少

项目成果

期刊论文数量(3)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Beck, Y.: "MHC peptides and tolerance induction" Molecular Medicine. (in press).
Beck, Y.:“MHC 肽和耐受诱导”分子医学。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
別宮好文: "MHCペプチドと免疫寛容" Molecular Medicine. (印刷中)34・7. (1997)
别宫义文:“MHC 肽和免疫耐受”《分子医学》(出版中)34・7(1997 年)。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
別宮好文: "MHCペプチドと免疫寛容" Molecular Medicine. 34.7(印刷中). (1997)
Yoshifumi Betsumiya:“MHC 肽和免疫耐受”《分子医学》34.7(出版中)。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ANDO Yuichi其他文献

ANDO Yuichi的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ANDO Yuichi', 18)}}的其他基金

Clinical and genetic factors of drug-induced QT interval prolongation in patients who receive cancer chemotherapy
接受癌症化疗的患者药物引起的 QT 间期延长的临床和遗传因素
  • 批准号:
    20590537
  • 财政年份:
    2008
  • 资助金额:
    $ 1.54万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Cancer treatment by non-myeloablative hematopoietic stem cell transplant with Flt3L gene transfection.
通过非清髓性造血干细胞移植和 Flt3L 基因转染进行癌症治疗。
  • 批准号:
    14571127
  • 财政年份:
    2002
  • 资助金额:
    $ 1.54万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Research of a model development for tooth loss prediction
牙齿缺失预测模型开发研究
  • 批准号:
    09672097
  • 财政年份:
    1997
  • 资助金额:
    $ 1.54万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)

相似国自然基金

基于PAR1介导的MHC class I表达探讨血府逐瘀汤逆转肺癌免疫逃逸的作用及机制研究
  • 批准号:
  • 批准年份:
    2022
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Defining MHC class I restricted antigen presentation to CD8 T cells in experimental AD and Tauopathy - Supplement
定义实验性 AD 和 Tau 病中 MHC I 类限制性抗原呈递至 CD8 T 细胞 - 补充
  • 批准号:
    10836880
  • 财政年份:
    2023
  • 资助金额:
    $ 1.54万
  • 项目类别:
Defining the role of tumoral MHC Class I Expression in Mediating Colorectal Cancer Racial Disparities
定义肿瘤 MHC I 类表达在调节结直肠癌种族差异中的作用
  • 批准号:
    10737111
  • 财政年份:
    2023
  • 资助金额:
    $ 1.54万
  • 项目类别:
Deeply analyzing MHC class I-restricted peptide presentation mechanistics across alleles, pathways, and disease coupled with TCR discovery/characterization
深入分析跨等位基因、通路和疾病的 MHC I 类限制性肽呈递机制以及 TCR 发现/表征
  • 批准号:
    10674405
  • 财政年份:
    2023
  • 资助金额:
    $ 1.54万
  • 项目类别:
SARS-CoV-2 infection and MHC class I function in bats
蝙蝠中的 SARS-CoV-2 感染和 MHC I 类功能
  • 批准号:
    10549369
  • 财政年份:
    2022
  • 资助金额:
    $ 1.54万
  • 项目类别:
Toll-like Receptor Control of MHC Class I Endocytosis
MHC I 类内吞作用的 Toll 样受体控制
  • 批准号:
    10557150
  • 财政年份:
    2022
  • 资助金额:
    $ 1.54万
  • 项目类别:
The role of MHC class I transactivator NLRC5 in COVID-19
MHC I 类反式激活因子 NLRC5 在 COVID-19 中的作用
  • 批准号:
    22H02883
  • 财政年份:
    2022
  • 资助金额:
    $ 1.54万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Determining cell-type specificity for a nonclassical MHC class I during an activity-dependent cortical critical period.
确定活动依赖性皮质关键期非经典 MHC I 类的细胞类型特异性。
  • 批准号:
    10705621
  • 财政年份:
    2022
  • 资助金额:
    $ 1.54万
  • 项目类别:
Determining cell-type specificity for a nonclassical MHC class I during an activity-dependent cortical critical period.
确定活动依赖性皮质关键期非经典 MHC I 类的细胞类型特异性。
  • 批准号:
    10426738
  • 财政年份:
    2022
  • 资助金额:
    $ 1.54万
  • 项目类别:
Toll-like Receptor Control of MHC Class I Endocytosis
MHC I 类内吞作用的 Toll 样受体控制
  • 批准号:
    10453097
  • 财政年份:
    2022
  • 资助金额:
    $ 1.54万
  • 项目类别:
Elucidating a molecular understanding of ILC2 MHC class I antigen cross priming
阐明 ILC2 MHC I 类抗原交叉引发的分子理解
  • 批准号:
    486527
  • 财政年份:
    2022
  • 资助金额:
    $ 1.54万
  • 项目类别:
    Studentship Programs
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了